WASHINGTON – The White House claims that prescription drug prices in the United States have seen the largest year-over-year decline in over 60 years. The administration of President Donald Trump attributes this development, among other things, to the TrumpRx program, which aims to allow Americans to obtain selected drugs at lower prices and deliver some medications directly to homes.
According to data from the U.S. Bureau of Labor Statistics (BLS), there has indeed been a significant decrease in the price level of prescription drugs. The year-over-year change reached approximately minus 3.1 percent, which represents the largest year-over-year decline in several decades. However, this figure does not mean that drugs are cheaper in the United States than they have been in the last 60 years.
The difference between these two statements is crucial. The BLS statistics refer to the rate of year-over-year price change, not that the prices of drugs themselves have reached a sixty-year low. However, the White House presented the statistic as another significant achievement of the Trump administration in the fight against high healthcare costs.
TrumpRx is a real program that offers discounts on selected drugs. The administration has also announced agreements with some pharmaceutical companies to lower prices. It pays particular attention to weight loss medications based on GLP-1 substances. According to the administration, the basic offerings of some of these products will start at approximately $150.
However, available statistics do not conclusively show that TrumpRx caused a nationwide decline in drug prices of 3.1 percent. The Consumer Price Index includes a broader range of factors, including changes in consumption patterns, discounts, insurance payments and public health insurance programs, or the shift of patients to cheaper alternatives.
It is also worth noting the broader development of American prices. According to the BLS, the overall Consumer Price Index rose year-over-year by 3.4 percent, and healthcare service prices increased by approximately 2.7 percent. Therefore, the decline in the prices of some drugs cannot be interpreted as a general decrease in healthcare or the U.S. economy.
```Therefore, the White House's statement is based on an actual statistical figure, but its political interpretation is much broader than what the data itself proves. The Trump administration may point to specific discounts and negotiated agreements, but without further evidence, it cannot be attributed to the TrumpRx program the historically significant decline in prescription drug prices.